2924-75-6

Usage

Aromatic compound

Consists of a benzene ring with a fluorine atom and an ethylsulfanyl group attached to it.

Industrial applications

Used in organic synthesis and as a building block for the synthesis of various pharmaceuticals and agrochemicals.

Precursor

Serves as a precursor in the manufacture of dyes, fragrances, and other fine chemicals.

Chemical properties

The presence of the fluorine atom and the ethylsulfanyl group gives the compound unique chemical properties.

Valuable in industry

Due to its unique properties, it is valuable in a variety of industrial applications.

Upstream product

• 352-34-1 4-fluoro-1-iodobenzene 
• 75-08-1 ethanethiol 
• 93-89-0 benzoic acid ethyl ester 
• 371-41-5 4-Fluorophenol 
• 80-40-0 ethyl ester of p-toluenesulfonic acid 
• 371-42-6 4-Fluorothiophenol 
• 75-03-6 ethyl iodide 
• 110-81-6 Diethyl disulfide 
• 371-40-4 4-fluoroaniline 
• 371-15-3 p-fluorothioanisole 
• 74-88-4 methyl iodide 

Downstream Products

• 144488-63-1 ethyl p-fluorophenyl sulfoxide 
• 144488-63-1 (S)-ethyl (p-F)-phenyl sulfoxide 
• 2924-67-6 fluoresone 

Relevant academic research and scientific papers

PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF

Compounds having activity as chemotherapeutic agents are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1a, R1b, R1c, R1d, L, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods for treating cancer (e.g., hematological cancers) are also provided.

Copper-Catalyzed Three-Component Coupling Reaction of Aryl Iodides, a Disilathiane, and Alkyl Benzoates Leading to a One-Pot Synthesis of Alkyl Aryl Sulfides

A copper-catalyzed three-component coupling reaction of aryl iodides, hexamethyldisilathiane and alkyl benzoates leading to alkyl aryl sulfides has been demonstrated. A disilathiane acted as both a sulfur source and a promoter of the sulfidation, and the alkyl moiety of the alkyl benzoate was effectively introduced on one side of the sulfide. Moreover, we found that the protocol can be expanded to the preparation of ethyl phenyl selenide with diphenyl diselenide.

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

BROMODOMAIN INHIBITORS

Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

The influence of electronic perturbations on the Sulfur-Fluorine Gauche Effect Dedicated to Prof. Dr. Antonio Togni on the occasion of his 60th birthday.

Herein, a solution phase NMR conformer population analysis is employed to probe the effect of remote electronic perturbations on the conformational equilibria of a series of para-substituted β-fluorosulfides (1), sulfoxides (2) and sulfone derivatives (3). Conformations that allow for stabilizing stereoelectronic (σC-H → σ?C-F) and electrostatic (Fδ-...Sδ+) interactions predominate: this is consistent with the Sulfur-Fluorine Gauche Effect. The molar fractions (χ) of the two possible gauche conformers correlate linearly with the electron-withdrawing aptitude of the para-substituent, rendering the system ideally suited for a Hammett-type analysis. Despite the clear influence that the remote para-substituents have on conformer population, this is superseded by the oxidation state on sulfur (II, IV, VI), where an increased preference for the gauche conformer follows the trend: sulfide sulfone sulfoxide. It is envisaged that this proof of concept in controlling conformer population, either by proximal (oxidation state) or remote tuning (para-substituent), will find application in molecular design.

Imidazo pyrazine compound, medicine composition of imidazo pyrazine compound and purpose of imidazo pyrazine compound

The invention provides an imidazo pyrazine derivative, a preparation method of the imidazo pyrazine derivative and a purpose of the imidazo pyrazine derivative as medicine. The invention provides a compound shown by a formula (I) and a physiologically acceptable salt, wherein each sign is defined as the specification. The compound can be combined with protein having the bromodomain structure domain so as to regulate the downstream signal path and to achieve a specific function; the compound can be used for various diseases relevant to the bromodomain structure domain protein; the compound can interfere with the combination of the acetylated histone and the Brd4 with the bromodomain structure domain; further, the transcription of the cancer gene and other relevant target genes is reduced, so that the compound can become effective treatment medicine for tumor.

Room temperature rapid functionalization of E-H bonds (E = O, N, S) via the metal-ligand cooperation mechanism

An arylpalladium PNF-type pincer complex reacts with water and anilines under very mild conditions, providing access to new PNO- and PNN-pincer complexes with concomitant hydrogen transfer to the ligand core. Such a metal-ligand cooperation mode allows for the irreversible double activation of even highly sterically hindered aniline molecules. With thiols, the activation mode depends on the nature of the substituent at the sulfur atom, with thiophenols giving products of C-S elimination.

DIHYDRO-PYRROLOPYRIDINONE INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).